MHMaria Izabel de Holanda

Maria Izabel de Holanda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maria Izabel de Holanda has a total of 117 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pegcetacoplan in C3 Glomerulopathy and Primary Immune-Complex MPGN

    by Carla M. Nester, Andrew S. Bomback, Gema Ariceta, Yahsou Delmas, Bradley P. Dixon, Daniel P. Gale, Larry A. Greenbaum, Seung Hyeok Han, Nicole Isbel, Christoph Licht, et al.

    Background: In VALIANT (phase 3 trial), pegcetacoplan (C3/C3b inhibitor) demonstrated significant proteinuria reduction at week 26 versus placebo (prespecified primary endpoint), stable eGFR, and glomerular C3 clearance in participants with C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. Methods: In VALIANT’s 26-week randomized controlled period, participants (≥12 years) received subcutaneous pegcetacoplan ( n =63) or placebo ( n =61) twice weekly plus supportive care. During the 26-week open-label period, all received pegcetacoplan. Here we report prespecified exploratory endpoints during the open-label period. Results: Fifty-nine participants who received pegcetacoplan and 55 who received placebo in the randomized controlled period completed the open-label period. At week 52, the pegcetacoplan-to-pegcetacoplan group maintained the 26-week proteinuria reduction (mean [95% confidence interval (CI)] urine protein-to-creatinine ratio changes from baseline: week 26, −67.1% [−74.9 to −56.8]; week 52, −67.2% [−75.8 to −55.4]). The placebo-to-pegcetacoplan group showed proteinuria changes of 3.2% (–9.6 to 17.9) (26 weeks of placebo), and −53.9% (−64.5 to −40.1) (26 weeks of pegcetacoplan [pegcetacoplan start [week 26] to week 52; post hoc]). In the pegcetacoplan-to-pegcetacoplan group, eGFR changes from baseline (least-squares [LS] mean [95% CI]) were −1.2 mL/min/1.73 m 2 (−5.6 to 3.2) (week 26) and –3.7 mL/min/1.73 m 2 (–8.9 to 1.6) (week 52). In the placebo-to-pegcetacoplan group, mean (95% CI) eGFR changes from baseline were –7.9 (–11.7 to –4.2) (week 26) and –4.7 (–9.1 to –0.3) (week 52); week-26-to-52 change was +3.0 (–1.0 to 7.1) (post hoc). Post hoc analyses of 52 weeks of pegcetacoplan ( n =118) showed proteinuria reduction (geometric mean [95% CI] −63.0% [−69.9 to −54.7]) and eGFR stabilization (LS mean [95% CI] change from realigned baseline, +0.1 [−3.8 to 4.0] mL/min/1.73 m 2 ). No new safety concerns were identified. No encapsulated meningococcal infections, deaths, or allograft losses occurred. Conclusions: Results demonstrate sustained proteinuria reduction and eGFR stabilization after 1 year of pegcetacoplan.

  • Open Access

    Glomerulopatia C3: avanços recentes e atualizações no manejo

    by Lilian Monteiro Pereira Palma, Maria Izabel Neves de Holanda Barbosa, Sanjeev Sethi

    Resumo A glomerulopatia C3 (C3G) é uma entidade clinicopatológica caracterizada por inflamação glomerular com dominância de C3 à imunofluorescência. A microscopia eletrônica é utilizada para determinar a localização e o tipo de depósitos, o que permite subdividir a C3G em glomerulonefrite C3 (GNC3) e doença de depósitos densos (DDD) com base em achados ultraestruturais. Ambas as entidades são progressivas, com cerca de 60% dos pacientes evoluindo para doença renal terminal (DRT) em 10 anos. A recorrência após o transplante renal ocorre em até 60% dos casos de C3G. Novos conhecimentos sobre a fisiopatologia—diferentes padrões de lesão, escores histopatológicos, coloração para apolipoproteína E, desregulação da via alternativa do complemento, que inclui autoanticorpos e mutações em fatores reguladores do complemento, bem como análises proteômicas—permitiram uma melhor compreensão dos diferentes perfis fisiopatológicos e apresentações clínicas, possibilitando um tratamento individualizado. O papel da nefroproteção está bem estabelecido na C3G, assim como em outras doenças glomerulares. O tratamento não específico com corticosteroides e imunossupressores está associado a uma taxa de resposta variável. No entanto, mais recentemente, os resultados de ensaios clínicos com inibidores proximais da via alternativa do complemento demonstraram melhora significativa na proteinúria e atenuação da redução da taxa de filtração glomerular estimada (TFGe). Com base nos resultados desses ensaios com medicamentos que atuam especificamente nas vias do complemento a montante, incluindo a via alternativa, novas opções de tratamento tornaram-se disponíveis para pacientes com C3G.

  • Open Access

    C3 Glomerulopathy: recent advances and an update on management

    by Lilian Monteiro Pereira Palma, Maria Izabel Neves de Holanda Barbosa, Sanjeev Sethi

    C3 glomerulopathy (C3G) is a clinicopathologic entity characterized by glomerular inflammation with dominant staining for C3 on immunofluorescence microscopy. Electron microscopy is used to determine the location and type of deposits, which further divides C3G into C3 glomerulonephritis (C3GN) and dense deposit disease (DDD) based on ultrastructural findings. Both entities are progressive, with about 60% of patients progressing to end-stage kidney disease (ESKD) within 10 years. Recurrence after kidney transplantation occurs in up to 60% of C3G cases. New knowledge about the pathophysiology—different patterns of injury, histopathological scoring, apolipoprotein E staining, dysregulation of the alternative complement pathway (including both autoantibodies to and mutations in complement regulatory factors), as well as proteomic analyses—has allowed a better understanding of different pathophysiological profiles and clinical presentations, enabling individualized treatment. The role of nephroprotection is well established in C3G, as it is for other glomerular diseases. Non-specific treatment with corticosteroids and immunosuppression is associated with a variable response rate. However, more recently, results from clinical trials with proximal complement inhibitors have shown significant improvement in proteinuria and attenuation of the decline in estimated glomerular filtration rate (eGFR). Based on the results of these trials involving drugs that specifically target the upstream complement pathways, including the alternative pathway, new treatment options have recently become available for patients with C3G.

  • Open Access

    EPI-CKD Brazil: point-of-care screening for chronic kidney disease during World Kidney Day

    by Viviane Calice-Silva, Patrícia Abreu, Maria Eliete Pinheiros, Ana Katarina de Cerqueira Delgado Lopes, Karla Cristina Petruccelli, Ana Wanda Barreto Marinho, Ana Flávia Moura, Felipe Costa Neves, Cláudia Maria Costa de Oliveira, Silvana Daher Costa, et al.

    Introduction: Chronic kidney disease (CKD) is a public health issue, with an estimated prevalence of 10% in Brazil, possibly underestimated due to regional inequalities and diagnostic limitations. The EPI-CKD Brazil study aimed to estimate the prevalence of estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2 in adults with risk factor for CKD, using point-of-care creatinine testing (POCTcr) during World Kidney Day 2025, and to assess regional variations and associated predictors. Methods: We conducted a multicenter cross-sectional study across 20 state chapters of the Brazilian Society of Nephrology, including individuals ≥ 18 years with at least one CKD risk factor (age > 60 years, hypertension [HTN], diabetes mellitus [DM], cardiovascular disease, obesity, chronic use of nonsteroidal anti-inflammatory drugs, history of acute kidney injury, bilateral kidney stones, or family history of CKD). Renal function was assessed using a rapid creatinine test (NovaMaxPro®–eGFR CKD-EPI 2021). Reduced eGFR was defined as < 60 mL/min/1.73 m2. Results: We analyzed 8,374 participants (66.9% women; median age, 58 years; BMI, 28.3 kg/m2; 46.2% mixed race). The frequency of reduced eGFR was 40.2% (n = 3,370), of whom 36% were in stages G3b–G5. Only 35.2% were aware of CKD risk factors. Significant regional differences were observed (ranging from 27.9% [Bahia] to 55.2% [Paraná]; p < 0.001). Independent predictors included age (OR = 1.032; 95%CI: 1.028–1.035), HTN (OR = 1.27; 95%CI: 1.15–1.40), and indigenous ethnicity as a protective factor (OR = 0.40; 95%CI: 0.20–0.89; p < 0.05). Risk increased by 23% for each additional risk factor. Conclusion: A high frequency of reduced eGFR and low awareness of CKD risk factors were observed. The study demonstrates the feasibility of POCTcr in screening strategies and reinforces the need for public policies to expand early diagnosis and strengthen primary care.


  • Open Access

    EPI-DRC Brasil: triagem da doença renal crônica com teste rápido de creatinina durante o Dia Mundial do Rim

    by Viviane Calice-Silva, Patrícia Abreu, Maria Eliete Pinheiros, Ana Katarina de Cerqueira Delgado Lopes, Karla Cristina Petruccelli, Ana Wanda Barreto Marinho, Ana Flávia Moura, Felipe Costa Neves, Cláudia Maria Costa de Oliveira, Silvana Daher Costa, et al.

    Resumo Introdução: A Doença Renal Crônica (DRC) é um problema de saúde pública, com prevalência estimada em 10% no Brasil, possivelmente subestimada por desigualdades regionais e limitações diagnósticas. O estudo EPI-DRC Brasil teve como objetivo estimar a prevalência de taxa de filtração glomerular estimada (TFGe) 60 anos, hipertensão (HA), diabetes (DM), doença cardiovascular, obesidade, uso crônico de anti-inflamatórios não esteroidais, histórico de injúria renal aguda, litíase renal bilateral ou história familiar de DRC). A função renal foi avaliada pelo teste rápido de creatinina (NovaMaxPro®-TFGe CKD-EPI 2021). Considerou-se TFGe reduzida quando <60 mL/min/1,73m2. Resultados: Analisamos 8.374 participantes (66,9% mulheres; mediana 58 anos; IMC 28,3kg/m2; 46,2% pardos). A frequência de TFGe reduzida foi 40,2% (n = 3.370), 36% estágios G3b–G5. Apenas 35,2% conheciam fatores de risco para DRC. Houve diferenças regionais significativas (de 27,9% [Bahia] a 55,2% [Paraná]; p < 0,001). Preditores independentes incluíram: idade (OR = 1,032; IC95%: 1,028–1,035), HA (OR = 1,27; IC95%: 1,15–1,40) e, como fator protetor, etnia indígena (OR = 0,40; IC95%: 0,20–0,89), p < 0,05. O risco aumentou 23% a cada fator de risco adicional. Conclusão: Observou-se elevada frequência de TFGe reduzida e baixo conhecimento sobre fatores de risco para DRC. O estudo demonstra a viabilidade do POCTcr em estratégias de rastreamento e reforça a necessidade de políticas públicas para ampliar o diagnóstico precoce e fortalecer a atenção primária.

  • Open Access

    Evaluating the Effectiveness of NOACs and LMWH in Reducing Mortality in Critically Ill Patients With COVID‐19

    by Rubens Carmo Costa‐Filho, Amarino Oliveira, Felipe Saddy, João Luiz Ferreira Costa, Marcela Santos Azevedo, Débora Fragoso Cerqueira, Víctor Hugo Amaral Gualberto, Maria Izabel Neves de Holanda Barbosa, Alda Maria Da‐Cruz, Marco Aurélio Horta, et al.

    Severe COVID‐19 is associated with increased prothrombotic and inflammatory responses, necessitating effective anticoagulation therapy. Novel oral anticoagulants (NOACs) are being explored as potential alternatives to low‐molecular‐weight heparin (LMWH). This retrospective observational cohort study compared the effectiveness and safety of NOACs and LMWH in reducing mortality among 76 critically ill, unvaccinated patients with confirmed SARS‐CoV‐2 infection. The cohort included 41 patients treated with LMWH and 35 with NOACs during their ICU stay. The primary outcomes was mortality, while secondary outcomes included deep vein thrombosis (DVT), bleeding episodes, and transfusion rates. Baseline characteristics, including demographic data and severity scores, were similar between the groups (mean age: LMWH, 74.5 ± 15.1 years [59% male]; NOAC, 71.6 ± 14.8 years [60% male]). Mortality was significantly higher in the LMWH group (51.21% [95% confidence interval (CI): 36.4–65.7]) compared to the NOAC group (20% [95% CI: 10.0–35.9]; p = 0.005), with standardized mortality ratios of 1.61 and 0.71, respectively ( p = 0.004). Elevated d ‐dimer levels were strongly associated with an increased risk of mortality. Deep vein thrombosis (DVT) occurred in 9.76% of patients in the LMWH group and 5.71% of those in the NOAC group ( p = 0.68). Bleeding and transfusion rates were comparable between the groups. The use of NOACs was associated with a significantly lower mortality rate compared to LMWH in critically ill COVID‐19 patients, reflecting an 81% reduction in the risk of death. These findings highlight the potential benefits of NOACs in the management of severe COVID‐19 and underscore the need for further research to optimize anticoagulation strategies and improve patient outcomes.

  • Open Access

    Recommendations for diagnosis and treatment of Atypical Hemolytic Uremic Syndrome (aHUS): an expert consensus statement from the Rare Diseases Committee of the Brazilian Society of Nephrology (COMDORA-SBN)

    by Helena Vaisbich Maria, Andrade Luis Gustavo Modelli de, Barbosa Maria Izabel Neves de Holan da, Castro Maria Cristina Ribeiro de, Miranda Silvana Maria Carvalho, Poli-De-Figueiredo Carlos Eduardo, Araujo Stanley de Almeida, Neto Miguel Ernandes, Penido Maria Goretti Moreira Guimarães, Sobral Roberta Mendes Lima, et al.

    Atypical hemolytic uremic syndrome (aHUS) is a rare cause of thrombotic microangiopathy (TMA) caused by the dysregulation of the alternative complement pathway. The diagnosis of TMA is made clinically by the triad: microangiopathic hemolytic anemia, thrombocytopenia, and organ damage (mainly acute kidney injury). The heterogeneity of clinical manifestation and the lack of a gold standard diagnostic test makes the precise diagnosis of aHUS a challenging process that may impact patient management. Until one decade ago, there was no specific treatment for aHUS and patients were submitted to plasma therapy (plasma exchange and/or plasma infusion) and/or liver transplantation, procedures that are not free of serious complications and that do not address the underlying pathophysiology of the disease. Since 2011, an anti-C5 complement monoclonal antibody has been approved by the Food and Drug Administration (FDA) for aHUS patients beginning a new era in treatment. Clinical trials on new complement inhibitors may also add to the treatment portfolio in the future. The Brazilian population is a mixed race with a unique genetic and clinical profile. This consensus aims to offer recommendations for the diagnosis and treatment of patients with aHUS in this population based on expert experience, data from the aHUS Brazilian Registry and literature review. The GRADE system was used to classify the quality of the evidence.


  • Open Access

    Recomendações para diagnóstico e tratamento da Síndrome Hemolítico-Urêmica Atípica (SHUa): uma declaração de consenso de especialistas do Comitê de Doenças Raras da Sociedade Brasileira de Nefrologia (COMDORA-SBN)

    by Vaisbich Maria Helena, Andrade Luis Gustavo Modelli de, Barbosa Maria Izabel Neves de Holanda, Castro Maria Cristina Ribeiro de, Miranda Silvana Maria Carvalho, Poli-De-Figueiredo Carlos Eduardo, Araujo Stanley de Almeida, Neto Miguel Ernandes, Penido Maria Goretti Moreira Guimarães, Sobral Roberta Mendes Lima, et al.

    A síndrome hemolítico-urêmica atípica (SHUa) é uma causa rara de microangiopatia trombótica (MAT) causada pela desregulação da via alternativa do complemento. O diagnóstico de MAT é feito clinicamente pela tríade: anemia hemolítica microangiopática, trombocitopenia e lesão de órgãos (principalmente injúria renal aguda). A heterogeneidade das manifestações clínicas e a ausência de um teste diagnóstico padrão-ouro tornam o diagnóstico preciso da SHUa um processo desafiador, podendo ter impacto no manejo do paciente. Até uma década atrás, não havia tratamento específico para a SHUa e os pacientes eram submetidos à terapia plasmática (troca de plasma e/ou infusão de plasma) e/ou transplante de fígado, procedimentos que não estão isentos de complicações graves e que não abordam a fisiopatologia subjacente da doença. Desde 2011, um anticorpo monoclonal anti- complemento C5 foi aprovado pela Food and Drug Administration (FDA) para pacientes com SHUa, dando início a uma nova era no tratamento. Ensaios clínicos sobre novos inibidores do complemento também podem aumentar o portfólio de tratamentos no futuro. A população brasileira é miscigenada, com um perfil genético e clínico único. Este consenso tem como objetivo oferecer recomendações para o diagnóstico e tratamento de pacientes com SHUa nesta população, com base na experiência de especialistas, dados do Registro Brasileiro de SHUa e revisão da literatura. O sistema GRADE foi utilizado para classificar a qualidade das evidências.


    • 1 January 2025
      • Vol. 47  (2) , e20240087
    Open Access

    Recommendations for diagnosis and treatment of Atypical Hemolytic Uremic Syndrome (aHUS): an expert consensus statement from the Rare Diseases Committee of the Brazilian Society of Nephrology (COMDORA-SBN).

    by Maria Helena Vaisbich, Luis Gustavo Modelli de Andrade, Maria Izabel Neves de Holanda Barbosa, Maria Cristina Ribeiro de Castro, Silvana Maria Carvalho Miranda, Carlos Eduardo Poli-De-Figueiredo, Stanley de Almeida Araujo, Miguel Ernandes Neto, Maria Goretti Moreira Guimarães Penido, Roberta Mendes Lima Sobral, et al.

    Atypical hemolytic uremic syndrome (aHUS) is a rare cause of thrombotic microangiopathy (TMA) caused by the dysregulation of the alternative complement pathway. The diagnosis of TMA is made clinically by the triad: microangiopathic hemolytic anemia, thrombocytopenia, and organ damage (mainly acute kidney injury). The heterogeneity of clinical manifestation and the lack of a gold standard diagnostic test makes the precise diagnosis of aHUS a challenging process that may impact patient management. Until one decade ago, there was no specific treatment for aHUS and patients were submitted to plasma therapy (plasma exchange and/or plasma infusion) and/or liver transplantation, procedures that are not free of serious complications and that do not address the underlying pathophysiology of the disease. Since 2011, an anti-C5 complement monoclonal antibody has been approved by the Food and Drug Administration (FDA) for aHUS patients beginning a new era in treatment. Clinical trials on new complement inhibitors may also add to the treatment portfolio in the future. The Brazilian population is a mixed race with a unique genetic and clinical profile. This consensus aims to offer recommendations for the diagnosis and treatment of patients with aHUS in this population based on expert experience, data from the aHUS Brazilian Registry and literature review. The GRADE system was used to classify the quality of the evidence.


  • Open Access

    Tip Lesion Most Frequent FSGS Variant Related to COVID-19 Vaccine: Two Case Reports and Literature Review

    by Emmy Marjorie Carvalho de Araújo, Marcos Adriano Garcia Campos, Andressa Monteiro Sodré, Maria Izabel de Holanda, Rodrigo Hagemann, Antonio Augusto Lima Teixeira Júnior, Natalino Salgado Filho, Precil Diego Miranda de Menezes Neves, Gyl Eanes Barros Silva

    Large-scale COVID-19 vaccination has been one of the most effective strategies to control the spread of the SARS-CoV-2 virus. However, several cases of glomerular injury related to the COVID-19 vaccine have been described in the literature. We report two cases of a tip lesion variant of focal segmental glomerulosclerosis (FSGS), which presented with significant proteinuria and improved after immunosuppression. In our literature review, the tip lesion variant of FSGS is currently the most frequent variant associated with vaccination against COVID-19. Prognosis is favorable and without significant alterations in the tubulointerstitial or vascular compartments. Adverse effects of vaccines need to be recognized early and will help us to understand the immune and pathological mechanisms of kidney damage.